Custom Search

Brand Name(s): ReoPro
CAS nš: 143653-53-6
(ab-siks-ih-mab)

What is Abciximab?

Abciximab is used to lessen the chance of heart attack in people who need percutaneous coronary intervention (PCI), a procedure to open blocked arteries of the heart.

A heart attack may occur when a blood vessel in the heart is blocked by a blood clot. Blood clots can sometimes form during PCI. Abciximab reduces the chance that a harmful clot will form by preventing certain cells in the blood from clumping together.

This medicine is regularly used with aspirin and heparin, which are other medicines used to keep the blood from clotting.

See more Product Info

Latest News

Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation, Coronary Microcirculation, and Platelet Function

The platelet glycoprotein (GP) IIb/IIIa inhibitors differ markedly in their pharmacokinetics,...

[more]

Abciximab Helpful in Thrombosis During Intracranial Aneurysm Repair: Presented at RSNA

The glycoprotein IIb/IIIA platelet activation inhibitor abciximab (ReoPro) appears successful in...

[more]

Medicure Announces New AGGRASTAT'R' Data at 2006 Scientific Sessions of the American Heart Association

Medicure Inc., a cardiovascular focused biopharmaceutical company, today announced that new data...

[more]

The Benefits of abciximab with clopidogrel for percutaneous coronary intervention Questioned

Primary findings from the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for...

[more]

Abciximab Shows No Benefits in Emergency Stroke Treatment Trial: Presented at ESC

Abciximab shows no efficacy in the treatment of patients with acute ischaemic stroke, while it does...

[more]

Use of this site is subject to the following terms of use